Zealand Pharma Partners with Benchling to Advance R&D of Engineered Peptide Medicines
SAN FRANCISCO and ZURICH, April 23, 2024 /PRNewswire/ -- Today Benchling announced that Zealand Pharma A/S, ("Zealand") a biotechnology company focused on the discovery and development of peptide-based medicines, has selected the Benchling R&D Cloud as its central source of truth for scientific data, collaboration, and insights. Teams across Zealand will use the Benchling R&D Cloud to capture, analyze, and share stability data internally and with their external contract manufacturing organization (CMO) partners, in compliance with GxP.
- Teams across Zealand will use the Benchling R&D Cloud to capture, analyze, and share stability data internally and with their external contract manufacturing organization (CMO) partners, in compliance with GxP.
- Scientists and partners can't be slowed down by siloed systems or a lack of consistent data," said Ludo Otterbein, Head of IT at Zealand Pharma.
- Benchling will provide Zealand with the digital data foundation that helps us safely and confidently scale new use cases and partners."
- "Benchling R&D Cloud gives Zealand the modern technology to streamline and accelerate its development, compliance, and partner needs.